Drug Trial Radar · NCT05565807
Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma
Last checked: Nov 19, 2026Latest source record: Aug 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
84
Planned (sponsor's estimate)
Start
Feb 9, 2023
Primary completion
Dec 31, 2026
Study completion Feb 19, 2028
Sponsor
- Lead sponsor
- Zhejiang ACEA Pharmaceutical Co. Ltd.Industry
- Sponsor type
- Industry
- First posted
- Oct 4, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase Ib/IIa, open-label, dose-escalation, and extension study to evaluate the safety and efficacy of an anti-CD38 antibody drug conjugate (STI-6129) in patients with relapsed or refractory multiple myeloma.
Conditions
- Relapsed or Refractory Multiple Myeloma
Interventions
STI-6129Biological
Anti-CD38 A2 human antibody drug conjugate (ADC) containing an antibody covalently bound to a duostatin tubulin inhibitor.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of adverse events(AEs)Time frame: Up to 2 years
- Overall response rate(ORR)Time frame: Up to 2 years
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Beijing Chao-Yang Hospital,Capital Medicine University
Beijing, Beijing Municipality, China · Recruiting
Peking university Third hospital
Beijing, Beijing Municipality, China · Recruiting
The first affiliated hospital ,Sun Yat-sen University
Guangzhou, Guangdong, China · Recruiting
The First Affiliated Hospital Zhejiang University School of Medicine
Hangzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.